Oxervate is a prescription eye drop approved for the treatment of neurotrophic keratitis. It is suitable for adults and children ages two years and older. Oxervate is a brand-name prescription drug ...

The FDA just greenlighted Italian firm Dompé’s eye drop Oxervate for the treatment of neurotrophic keratitis (NK), a rare type of eye disease. While the condition may sound unfamiliar, the approval is ...

Please provide your email address to receive an email when new articles are posted on . There is more than one way to treat neurotrophic keratopathy. In a debate on the topic, Fasika Woreta, MD, MPH, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — Patients with stage 1 neurotrophic keratitis ...

OxervateUSPackag_1534470705843-3-HR The safety and efficacy of Oxervate was evaluated in 2 independent, double-masked, randomized, multicenter, controlled clinical trials involving patients with ...

A little over one year after European regulators gave their nod, regulators in the U.S. cleared for marketing Milan-based Dompé farmaceutici SpA's Oxervate (cenegermin) eye drops for neurotrophic ...

Patients in the UK will get early access to Dompé farmaceutici's neurotrophic keratitis drug Oxervate (cenegermin), the Medicines and Healthcare products Regulatory Agency (MHRA) announced Wednesday.

The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that ...

MILAN, Nov. 26, 2020 /PRNewswire/ -- Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive ...

MILAN, Nov. 26, 2020 /PRNewswire/ -- Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive ...